I Used to Believe 'Good' Health Insurance Was Actually Good. I Was Wrong

By Crystal Lindell

Chronic pain is not a patient teacher— especially when you combine it with a private health insurance system. 

I first developed debilitating chronic pain in 2013, and I’ve been learning to live with it ever since. Over the last 12 years, I’ve been forced to learn a lot about the realities of what it’s like to live in a country with a mostly private healthcare system.

While I am currently among the lucky few who are able to mostly manage my pain with daily opioid medications, I am also now among the 26 million people in the United States who don’t have any health insurance. As a result, I pay for all of my doctor visits and prescriptions in cash.

It wasn’t always this way though. 

When I first got sick, I had what I would have described as “good health insurance” through my job. I kept that insurance until I was laid off in 2022. But in those nine years, even with that insurance, I still managed to rack up more medical debt that I could ever pay off in my lifetime. 

Until I actually needed my insurance and learned how it works, I really did believe that having it would somehow shield me from drowning in medical debt.

I was wrong.

It turns out that even with good health insurance, you can still rack up thousands or even tens of thousands of dollars in medical bills pretty quickly — even without being hospitalized or undergoing surgery.

Having health insurance means you likely pay a relatively small co-pay for routine appointments — which is good when all you need are the routine appointments.

But the minute you start needing medical tests, specialist care, physical therapy, prescriptions, and ER visits? All bets are off.

It’s partly because many of those things are not covered by co-pay programs. They fall under extremely high deductible programs that can require you to spend thousands of dollars out of your own pocket before insurance kicks in. 

Co-pays can also add up fast when you need to see a different doctor every other week, and all of them prescribe you a different name-brand prescription and a different long-term treatment.

For example, if you have a $50 co-pay for every physical therapy appointment and you need physical therapy three times a week for 12 weeks – that’s suddenly $1,800 right there. 

Or if you need a prescription that doesn’t have a generic available, it can literally be hundreds of dollars each month just for a co-pay.

The first few years I had chronic pain, I was desperate for answers and help, so I saw every specialist I could and got every medical test and treatment that was offered to me. It made sense at the time. After all, wasn’t that the whole point of why I was paying hundreds of dollars a month in premiums for my good health insurance?

But the thing about all those doctor visits and treatments is that nobody ever discusses cost with you beforehand. Instead, you only find out when you get an enormous bill in the mail weeks or even months later. 

Suddenly, the simple X-ray means you somehow owe $3,000. 

I was not making much money at the time, and I make even less money now because I’ve had to scale back my life to accommodate my chronic pain. So a lot of those medical bills just ended up with medical collection agencies, which destroyed my credit. 

The frustrating thing is that most of the money I owe was for doctors who missed my eventual diagnosis of Ehlers-Danlos Syndrome, and for treatments that weren’t nearly as effective as cheap generic hydrocodone. 

But it didn’t matter that I was misdiagnosed or how little help I got from those treatments, because I still ended up with thousands of dollars of medical debt all the same.

I always say, everyone loves their private health insurance, right up until they actually need to use it. Then they find out just how little it actually covers.

We can do better in this country. Even incremental changes to regulations around insurance companies and medical billing practices would make a huge difference. And of course, there’s always the option of universal health care, which could be modeled after similar programs that most developed countries around the world already have. 

We have the most expensive healthcare system in the world, nearly $5 trillion annually or $14,570 per person. Much of its is spent on administration and insurance billing.

Nobody deserves to end up with thousands of dollars of medical debt just because they got sick. We must do better, because only then can patients focus on what really matters: Getting better.

How the Curves in Your Spine Cause Back Pain

By Dan Baumgard

Over 60% of us will suffer from lower back pain at some point in our lives. Without question, it’s the leading cause of disability across the globe.

Your spine is comprised of 33 bones known as vertebrae, which are stacked one on top of the other. The resulting column is divided into five segments: cervical (in the neck), thoracic (at the same level as the chest), lumbar (at the level of the abdomen) and sacral (connecting with the pelvis). The fifth, the coccyx, is located at the very bottom of the spine (the tailbone) – and is very painful when injured.

The vertebrae are connected by multiple joints, including discs which allow the spine to move in multiple directions. Though we might think the spine should appear straight, it naturally curves forward and backwards so it can perform all of its important functions.

But many conditions can cause the spine to curve more than it should. This can not only lead to pain, but potentially a whole host of other health troubles too.

Dowager’s Hump

The spine also supports the weight of the body, protects the spinal cord and helps the body to bend, flex and twist. The thoracic region attaches to the ribs and naturally curves backwards – this curve is known as the thoracic kyphosis.

But sometimes, the curve of the thoracic kyphosis becomes more accentuated and visible – often as a result of osteoporosis (where bones become weaker), age-related changes to the back muscles and vertebrae, or long-term poor posture.

The medical name for this condition is hyperkyphosis, though it’s sometimes referred to as “dowagers hump” as it’s around two to four times more common in women.

A stooped posture with rounded shoulders (or “hunchback” appearance) is typically a sign of hyperkyphosis.

In some cases, it may become so extreme as to impact breathing since the chest can’t inflate properly. It can also affect swallowing since the neck becomes more horizontal and the gullet potentially narrowed.

Dowager’s hump

And of course pain and stiffness typically arise. This is a common theme for most patients with abnormal curvature of the spine, as the vertebrae lose their ability to move, and nerves arising from the spinal cord can become compressed.

Scoliosis

Another type of deformity that can occur in the spinal column affects not only how it bends forward and backwards, but also side-to-side.

Scoliosis occurs when the vertebrae either curve sideways, rotate in relation to each other, or collapse. This produces a variety of different deformities, ranging in size and severity.

The underlying causes of scoliosis are widespread. Sometimes bones can become deformed as a result of trauma, cancer or an infection (such as tuberculosis).

Scoliosis can also be present from birth, or arise from neurological disorders in early years – such as cerebral palsy.

As well as back pain, patients may also notice postural signs as scoliosis evolves. Their shoulder blades or ribcage can stick out more, and clothes may fit differently on their body.

SCOLIOSOS

Slipped and Fused Spines

Individual vertebrae in any part of the spine can sometimes also become displaced as a result of trauma, wear and tear, or certain health conditions (such as osteoporosis).

This means that instead of standing in a regular stack, a vertebra slips forward, and out of line. This condition is given the long and practically unpronounceable name, spondylolisthesis.

In doing so, this displacement can trigger nerve compression. If the sciatic nerve – the largest in the human body – gets compressed, it can lead to symptoms of sciatica. These are namely pain, pins and needles, or numbness in the back of the leg or buttock.

The vertebrae in the lower back can sometimes also fuse abnormally together. A condition called ankylosing spondylitis can trigger inflammation in the spinal joints and discs, which then harden over time. Another name for the condition is bamboo spine, since the now rigid and inflexible column resembles a tough stalk of bamboo.

FUSED SPINE

Managing Back Pain

Managing these conditions – and the pain they cause – will depend largely on the size of the deformity and what has caused it in the first place. Even a small spinal deformity can be significant.

For scoliosis for instance, braces to correct the spine as it grows may work to manage small defects in younger patients. But corrective surgery is often required to fix larger deformities and those which don’t respond to bracing.

Taking account of posture and bone health can also help prevent developing a spinal problem later in life. Using exercise to build a strong back and shoulders and avoiding slouching are solid measures, too. Managing associated conditions such osteoporosis with diet, medication and resistance training can also help.

Surgical intervention may be required in other situations – for instance, to decompress nerves that have become trapped or squashed.

Your spine is truly an architectural wonder. It’s far from a straight and rigid column – and capable of more than you’d ever expect. But this unique structure can lend itself to problems, especially when natural curves become deformities. The age-old adage “strengthen your back, strengthen your life” is a motto we should all be regularly reminded of, and to seek medical advice accordingly should back pain arise.

Dan Baumgardt is a medically-qualified clinical neuroscientist and anatomist. He is Senior Lecturer in the School of Psychology and Neuroscience at the University of Bristol

This article originally appeared in The Conversation and is republished with permission.

Trump: ‘Don’t Take Tylenol If You’re Pregnant’

By Pat Anson

The Trump administration is advising women not to use acetaminophen (Tylenol) for pain and fever during pregnancy due the risk of their babies developing autism. About two-thirds of expectant mothers in the United States use acetaminophen.

Speaking at the White House, President Trump and Health and Human Services Secretary Robert F. Kennedy also linked childhood immunization shots to rising rates of autism, which now affects about 1 in 31 American children.

“They pump so much stuff into those beautiful little babies, it's a disgrace. I don't see it. I think it's very bad. They're pumping -- it looks like they're pumping into a horse. You have a little child, a little fragile child and you get a vat of 80 different vaccines, I guess, 80 different blends and they pump it in,” Trump said in a rambling statement that veered from Tylenol to vaccines and back again.

“And I will say there are parts of the world that don’t take Tylenol. I mean, there’s a rumor. And I don’t know if it’s so or not, that Cuba, they don’t have Tylenol because they don’t have the money for Tylenol and they have virtually no autism.”

Cuba does in fact have autism, although at low rates. It also has limited supplies of acetaminophen, which is known as paracetamol outside the U.S.

Acetaminophen is one of the most widely used over-the-counter pain relievers in the world, and medical professionals generally consider it one of the safest ways to relieve pain and fever. High fevers during pregnancy have been associated with birth defects and miscarriages, while poorly treated pain can lead to depression, insomnia and other harms to pregnant women.

The FDA warns expectant mothers not to take other over-the-counter pain relievers, such as aspirin and ibuprofen, because they can damage the kidneys of unborn babies.

The UK’s National Health Service (NHS) maintains that it is safe for pregnant women to use paracetamol. “Paracetamol is the first choice of painkiller if you're pregnant or breastfeeding. It's been taken by many pregnant and breastfeeding women with no harmful effects in the mother or baby,” the NHS says on its website.

Kenvue, the maker of Tylenol, also disputes any link between acetaminophen and autism.

“We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” the company said in a statement.

In recent years, a handful of studies have linked the use of acetaminophen by pregnant women to autism, Attention-Deficit Hyperactivity Disorder (ADHD), and hyperactivity in children, although the evidence is not conclusive. A large 2021 study in Europe found that women who took acetaminophen while pregnant were 19% more likely to have children with autism.

“Today, the FDA will issue a physicians’ notice about the risk of acetaminophen during pregnancy and begin the process to initiate a (warning) label change. HHS will launch a nationwide public service campaign to inform families and protect public health,” Kennedy said.

“HHS wants to encourage physicians to exercise their best judgment and the use of acetaminophen for fevers and pain in pregnancy by prescribing the lowest effective dose for the shortest necessary duration and only when treatment is required.”    

‘Outright Lies and Dangerous Advice’ 

The FDA’s current warning label for acetaminophen cautions people about the risk of liver damage and other side effects, but does not specifically warn pregnant women about using the pain reliever. The agency said in 2015 that the evidence was “too limited” to justify such a warning.  

“The announcement on autism was the saddest display of a lack of evidence, rumors, recycling old myths, lousy advice, outright lies and dangerous advice I have ever witnessed by anyone in authority in the world claiming to know anything about science,” Arthur Caplan, PhD, founding head of the Division of Medical Ethics at NYU’s Grossman School of Medicine told The New York Times.

One of the reasons autism rates have risen in the U.S. is that its definition changed. Once considered extremely rare, a task force added Asperger’s syndrome to the list of autistic conditions, which resulted in a surge of new cases. Over the next decade, autism rates surged from 1 in 2,500 children to 1 in 31.

“The rapid rise in autism cases is not because of vaccines or environmental toxins, but rather is the result of changes in the way that autism is defined and assessed — changes that I helped put into place,” Dr. Allen Frances, a psychiatrist who led the task force, wrote in a recent op/ed in The New York Times.

“Our intentions were good, but we underestimated the enormous unintended consequences of adding the new diagnosis. The resulting explosion in cases included many instances of overdiagnosis — children were labeled with a serious condition for challenges that would better be viewed as a variation of normal. It also sowed the seeds of conspiracy theories and anti-vaccine beliefs as people wondered how to explain the rising cases.”

An FDA statement today also cautioned about drawing too many conclusions about links between autism and acetaminophen.

“It is important to note that while an association between acetaminophen and neurological conditions has been described in many studies, a causal relationship has not been established and there are contrary studies in the scientific literature,” the FDA said in a press release.

“It is also noted that acetaminophen is the only over-the-counter drug approved for use to treat fevers during pregnancy, and high fevers in pregnant women can pose a risk to their children. Additionally, aspirin and ibuprofen have well-documented adverse impacts on the fetus.”

‘We Are Rookies’: Chaos and Confusion as Vaccine Skeptics Control CDC Panel

By Arthur Allen and Renuka Rayasam, KFF Health News

Public health officials watched with dread as a panel shaped by the Trump administration took up an agenda to begin dismantling six decades of vaccination development and progress.

But while the result seemed foretold, the debate was far from unanimous.

The Advisory Committee on Immunization Practices, or ACIP, met at a satellite campus of the Centers for Disease Control and Prevention because the agency’s headquarters were still smashed up from a deadly gun attack last month by a man who said the covid vaccine had made him depressed and suicidal.

Health and Human Services Secretary Robert F. Kennedy Jr. has made it clear he wants the panel to change the CDC’s childhood immunization schedule, which establishes, sometimes with legal authority, which vaccines are to be mandated, paid for, and administered by states, insurers, and doctors across the country.

Kennedy fired the 17-member panel in June and has so far restocked it with 12 people, including outspoken critics of vaccination. On Sept. 18, the new panel’s discussions reflected its thin expertise and ignorance of how the vaccination schedule came to be. Scientific questions answered decades ago were asked as if they were brand-new.

“We are rookies,” said biostatistician Martin Kulldorff, the committee’s chair, noting many “technical issues that we might not grasp as of yet.”

Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, watched the telecast anxiously.

“It reminds me when as children we would have a mock United Nations meeting,” he said. “This would be like that, except we would have actually made decisions for the United Nations.”

In one key vote, the committee came close to recommending that COVID-19 shots only be available by prescription. Kulldorff broke a 6-6 tie by voting against the proposal as chair.

The ACIP panel then voted unanimously in favor of a process called “shared clinical decision making,” in which patients are encouraged to speak to a doctor, nurse or pharmacist before getting their COVID shots.

"In the prior seasons of COVID, we've had routine vaccine access — you or I could go to our pharmacy or doctor's office and just get our vaccine, it was encouraged as a routine recommendation," said Jen Kates, director of global health and HIV policy at KFF.

‘Recycled Anti-Vax Talking Points’

Kennedy’s CDC accomplished what 30 years of public health attempts to fight anti-vaccine sentiment hadn’t: a head-to-head comparison of evidence and arguments. But while the winner was clear in the eyes of most experts, some doubted the result would be good.

“The whole purpose of the people on this committee is to circulate these old recycled anti-vax talking points,” said Sean O’Leary, a professor of pediatrics at the University of Colorado who previously was a liaison from the American Academy of Pediatrics to ACIP.

On Friday morning, he said, a colleague had a mother in his practice who refused the measles, mumps, and rubella vaccine “because she heard something bad in the news about it last night.”

Until now, public health owned places like ACIP, while vaccine foes and skeptics dominated social media. At this meeting, the skeptics had moved onto public health’s turf — where sometimes flimsy arguments and expertise were exposed.

Pharmacist Hillary Blackburn, for example, asked why children needed two measles, mumps, and rubella shots. ACIP began recommending a second shot in 1989 during a deadly measles outbreak. The two-shot regimen provided more than 95% immunity and led to the virtual elimination of measles from the United States. This year under the Trump administration more than 1,400 cases have been reported, mostly in unvaccinated people.

In one noteworthy gaffe, ACIP member Retsef Levi, a Massachusetts Institute of Technology operations management professor, misinterpreted data from a graph showing declines in hepatitis B in the United States since the 1980s. While rates had fallen in older groups, Levi said, cases in babies hadn’t declined substantially since 2005, when he inaccurately said a birth dose was first recommended.

“Where’s the argument to vaccinate even younger children at all,” he said. “Where is the benefit?”

In fact, the recommendation for a newborn shot began in 1991 and was reinforced and expanded in 2005. The first generation of hepatitis B-vaccinated babies are well into their 30s now.

“As time goes on,” CDC scientist Adam Langer patiently explained, “the people who benefited from the change in policy at the very beginning of the policy are moving into different age groups.”

Kulldorff, Levi, and committee member Evelyn Griffin, a gynecologist, also suggested that vaccines shouldn’t be recommended unless they are tested in placebo trials, which would require certain children not to be vaccinated — a practice considered unethical.

Kulldorff began the meeting defiantly. He did not mention the CDC shooting, but disparaged former agency officials Kennedy had forced out and challenged nine former CDC directors to a debate.

He also asked if anyone in the audience would eat a hot dog laced with thimerosal, the mercury-containing preservative the committee banned from influenza vaccines at its last meeting. (No one has ever offered thimerosal as a condiment, but years of study showed the minuscule amounts in vaccines did no harm).

At the June meeting, HHS censored a CDC appraisal of thimerosal while inviting an anti-vaccine activist to present an error-filled criticism of the substance. But on Sept. 18 the panel got what looked like straight science from CDC professionals.

As the committee prepared to debate ending a 34-year-old ACIP recommendation for babies to get a dose of the hepatitis B vaccine at birth, CDC career scientists Langer and John Su presented evidence of the vaccine’s safety and benefits.

Langer also laid out the history of the fight against hepatitis B — including the failed effort to control the disease by vaccinating people most at risk, including people who use drugs, sex workers, and pregnant women who tested positive for the virus. Years of trial and error showed that in the U.S., at least, it was necessary to vaccinate newborns to really knock down the disease.

Levi, who frequently mentions the vaccination status of his own six children, challenged the idea that a healthy baby from a “normal” household — one with no history of drug use or prostitution — needed the vaccine.

Cody Meissner, one of three panel members who put up a spirited defense of the status quo in the hepatitis debate, noted that when it comes to vaccination campaigns, “the more we try and define a target group to vaccinate, the less successful we are.” Meissner, a Dartmouth College professor, has published studies of vaccines and the diseases they fight since the 1970s.

Long-observed tropes of vaccine skepticism were abundant on the first day of the meeting. Levi praised a 2004 study from Guinea-Bissau, an outlier that suggested that babies, especially females, were more likely to die if they got a hepatitis B shot. Other panelists said the study, performed in a poor country with high infant mortality where children got an outdated vaccine, wasn’t relevant. But more studies were needed in general, Levi said. “We sit here with very lousy evidence,” he said.

Nurse Vicky Pebsworth of the National Vaccine Information Center, which opposes all vaccine mandates, frequently brought her own selective research into the meeting. She read off the names of studies other panelists hadn’t received to back her arguments that vaccines under discussion were not safe.

But while “too many, too soon” is a common anti-vaccine refrain, Judith Shlay from the National Association of County and City Health Officials, which had a nonvoting chair at the meeting, used it to support the current schedule. She pointed out that the panel’s debate over a combination measles, mumps, rubella, and varicella shot for children would result in a separate shot for the virus that causes chickenpox, adding to the number of inoculations on the childhood schedule.

“Some parents want to have fewer injections,” she said.

With an 8-3 vote at the end of the day, the committee nonetheless recommended separate vaccinations for MMR and chickenpox.

Everyone seemed puzzled about what had transpired with an ensuing vote on whether the Vaccines for Children Program, which pays for more than half of childhood vaccinations, should respond to ACIP’s new recommendation. The panel revoted on the issue on Sept. 19.

Nor could anyone provide a clear answer as to what prompted the committee’s discussion and planned vote on the birth dose of hepatitis B vaccine, since there was no new evidence suggesting any harm from it.

Two of Kennedy’s senior aides, both vaccine skeptics, pushed the hepatitis B discussion onto the ACIP schedule, according to testimony at a Sept. 17 Senate hearing by former CDC chief medical officer Debra Houry, who resigned to protest administration policies.

ACIP member Robert Malone, who has claimed that mRNA vaccines are dangerous, said hepatitis B was on the agenda because it is given to newborns at birth and of special concern to parents newly awakened to vaccine doubt. He appeared to nod off during a CDC staff presentation on the safety of the hepatitis B shot.

Vaccination of babies has always triggered parents. The 19th-century poet Alexander Hope Hume described evil vaccinators who turned “the rosy darling” who “crows with glee” into “a wailing infant” whose every vein “ferments with poison.”

The agenda item was not really about the merit of the hepatitis B vaccine, Malone acknowledged.

“The signal that is prompting this is not one of safety; it’s one of trust,” he said.

But in the end, the committee reconsidered what would have been its first drastic move to reverse a successful U.S. vaccination campaign. It postponed its vote on the hepatitis B birth dose.

KFF Health News is a national newsroom that produces in-depth journalism about health issues.  

Former Secretary of Veterans Affairs Calls for ‘Opioid-Free VA’

By Crystal Lindell

An alarming new column in The Hill is advocating for an opioid-free Veterans Affairs health system by 2030 – a move that would leave countless veterans and their families without effective pain relief.

Headlined “Whiskey, tobacco, and pain pills: The VA can be an opioid-free health system,” the op/ed was written by David Shulkin, MD, who was Secretary of Veterans Affairs in the first Trump administration, and the VA’s Under Secretary of Health in the Obama administration.

His opening line gets straight to the point he’s trying to make: “There is a time for everything. Now is the time for the Department of Veterans Affairs to go opioid-free.”

His column is promoting a dangerous message, and I fear that Shulkin’s credentials will lead people to take his stance seriously. It’s especially abhorrent because veterans are more likely to have chronic pain and have suicide rates twice as high as civilians, often due to poorly treated pain.

The VA and Department of Defense medical guidelines already discourage opioids from being prescribed for chronic pain, especially for younger patients of military age. The guidelines only allow for short-acting opioids to be prescribed for short-term acute pain.  

Shulkin frames opioids as a sort of magic-spell curse that can ruin lives after just one dose:

“The real opportunity lies in preventing opioid initiation,” Shulkin wrote. “The VA’s comprehensive, integrated system makes it uniquely positioned to lead the nation in eliminating opioid use and become the first opioid-free health system in the country. While it would be inappropriate to abruptly discontinue opioids for current chronic users, the VA could immediately begin limiting opioids for acute pain and adopt new alternatives. 

Shulkin claims that over half of veterans receive opioids for post-operative acute pain, as though that number is too high. But having opioid medication after surgery isn't just common practice, it's the most humane response. And there’s little evidence it leads to opioid addiction.

In fact, I’d go so far as to say that the fact that only half of veterans get opioids post-op is probably too low. Of course, I couldn’t fact check Shulkin’s numbers because the link he uses to validate his claim about how many veterans receive opioids post-op doesn’t even work. It just goes to a “404 error” page not found.  

Shulkin also claims that “roughly 10 percent” of veterans develop opioid addiction after surgery. But the link provided for that misleading claim takes you to a large meta-analysis study of over 4 million chronic pain patients around the world (mostly civilians), which has no relevance to how many U.S. veterans become addicted after surgery.

As noted in the headline to his column, Shulkin also compares opioids to alcohol and tobacco, citing the fact that VA doctors used to recommend both to patients to help make them “more comfortable.”  

“Just as we no longer prescribe alcohol or allow tobacco on VA campuses, the day will come when we look back and wonder why opioids were ever part of routine care,” he writes. 

Of course, there are glaring differences between opioids and those two substances: Opioids require a prescription, while alcohol and tobacco can be bought over the counter. They’re also involved in many more deaths than prescription opioids. 

To be frank, if patients could go out and purchase hydrocodone as easily as they can buy whiskey or a pack of cigarettes, I wouldn’t have a problem with what Shulkin is saying. Patients lacking a prescription from the VA would still have the option to treat their pain how they saw fit — whether or not a doctor approved of the methods would be irrelevant. 

Unfortunately, that’s not the case. And as such, trying to make the VA opioid-free within five years is inhumane. 

‘Additional Advances Are Emerging’

Of course, since Shulkin is advocating for zero opioid prescriptions, one might assume that he would at least offer a list of reasonable non-opioid pain relieving alternatives. But here too, his evidence is lacking. 

His first suggestion is a selective sodium channel blocker called Journavx (suzetrigine), which was recently approved by the FDA, even though it’s no more effective than a low dose of Vicodin. 

According to Yale Medicine, Journavx has very specific limitations. It’s "not a cure-all" and is only meant for moderate-to-severe acute pain, which is short-term pain after trauma or surgery. 

"This means, based on the current evidence, that it would likely be used primarily in the hospital setting and only for a few days," says Robert Chow, MD, a Yale Medicine anesthesiologist and pain management specialist.

Shulkin says "additional advances are emerging” for other non-opioid alternatives, including drugs targeting peptide-receptors that “appear to provide effective pain relief.”

So to recap, Shulkin wants the entire VA system – which provides healthcare to over 8 million military service members, veterans and their families – should go opioid free because we now have one sodium channel blocker and "additional advances are emerging."

Shulkin admits "it would be inappropriate to abruptly discontinue opioids” for long-term patients on opioids. But something tells me that such a warning would be ignored if the VA ever actually did go "opioid free," given the fact that many veterans have already been abruptly tapered off opioids.

I suspect that if Shulkin ever needed opioids for his own pain, he would not hesitate to take them. His is the type of column that is only written about other people’s pain – and other people’s pain is always easy to endure. 

I hope that his proposal is ignored and ridiculed as the nonsense it is. But after witnessing opiophobia for the last decade, I worry that the opposite will happen, and that policymakers will take Shulkin’s ideas seriously. 

Opioids aren’t just helpful – for many veterans they are necessary. And any medical professional advocating for their elimination should not be working in medicine at all. 

If we want to make the world a better place, we need to take pain seriously and treat it as the grave condition it often is. That means giving patients access to opioids when they need them. 

Early Receipt of Opioids Reduces Hospitalization of Children with Sickle Cell Disease

By Pat Anson

Early administration of opioids for pain relief in emergency departments significantly reduces the chances of a child with sickle cell disease being hospitalized, according to a large new study published in JAMA Pediatrics. 

Sickle cell disease (SCD) is a genetic disorder that causes red blood cells to form in a crescent or sickle shape, which creates painful blockages in blood vessels. About 100,000 Americans live with sickle cell disease, primarily people of African or Hispanic descent.

It’s not uncommon for someone with SCD to visit an ER a few times each year due to pain or complications such as anemia, stroke, infection and organ failure. Many patients with SCD feel stigmatized when they visit an ER, where their pain is not taken seriously and they are seen as drug seekers. That delays their treatment, even though medical guidelines recommend early treatment with opioids and other pain relievers.    

“If we can stabilize and treat patients’ pain, they won’t need to be admitted to the hospital, where they would miss school, their families would miss work, and it’s disruptive to their lives,” said co-author Elizabeth Alpern, MD, Professor and Vice Chair in the Department of Pediatrics at Northwestern University Feinberg School of Medicine.

Alpern and her colleagues reviewed over 9,000 ER visits by 2,538 children with an uncomplicated SCD pain flare between 2019 and 2021. Their findings offer some of the first evidence that faster pain management with opioids can lead to better outcomes for pediatric SCD patients.

Children who received their first opioid dose within 60 minutes of arrival in the ER were 15% less likely to be hospitalized. The odds of hospitalization dropped even further when a second dose was administered within 30 minutes of the first. 

“We were able to statistically show that if patients receive a timely first dose of opioid medications and a timely second dose of opioid medications, we could drastically reduce the number of hospital admissions within this population,” said co-author Jacqueline Corboy, MD, Assistant Professor of Pediatrics in the Division of Emergency Medicine at the Feinberg School of Medicine. “This is the first study that shows concrete evidence, so this is really important.” 

The study was a collaborative effort among 12 pediatric hospitals. Two smaller, single-site studies showed no association between early receipt of opioids and lower odds of hospitalization.

SCD patients have few alternatives to opioids for pain relief. Last year Pfizer took the sickle cell medication Oxbryta off the market over concerns that it could be causing deaths and other complications. A 2022 study also found that SCD patients given corticosteroids are more likely to be hospitalized with severe pain.

Compared to other chronic illnesses, SCD has received little attention from researchers and pharmaceutical companies, resulting in a lag in the development of new treatments. Until 2018, only one drug was approved by the FDA to treat sickle cell patients. Bone marrow and stem cell transplants are currently the only curative therapies for SCD.

How Trump’s False Claim That 300 Million People Died From Drugs Impacts Pain Patients

By Crystal Lindell

President Donald Trump recently claimed that "300 million people died” from drug-related causes last year.

If that were true, it would mean that nearly the entire population of the United States – 342 million people –  died from a drug overdose in 2024.

Trump’s claim is so absurd, that it’s difficult to know what he was trying to say or what he may have meant.

The comment came during a Q&A with reporters, when he was asked about the U.S. strike on a supposed drug-smuggling boat off the coast of Venezuela, an attack the president of Venezuela called "illegal."

"What's illegal are the drugs that were on the boat and the drugs that are being sent into our country. And the fact that 300 million people died last year from drugs. That's what's illegal," Trump said.

In a community note on X/Twitter, the site’s fact checkers noted that 62 million people worldwide died from all causes in 2024, which “makes it impossible for 300 million people to have died of one single cause.” 

Obviously, the real numbers for drug-related deaths are significantly lower than 300 million. In reality, there were about 80,000 U.S. overdose deaths in 2024. Globally, 600,000 deaths were attributed to drug use in 2019, the most recent data available.

The World Health Organization reported there are 3 million deaths annually due to alcohol and drug use. But a majority of those — 2.6 million — were attributed to alcohol consumption.

So, Trump may have seen the “3 million” and misremembered it as "300 million," while also ignoring the fact that most of those deaths were related to alcohol.

It’s also possible he meant 300-thousand drug deaths. The president has actually used that number in the past, while adding that he doesn’t believe the overdose numbers the government produces. .

“We don’t want drugs killing our people. I believe we lost 300,000. You know, they always say 95, 100,000. I believe they’ve been saying that for 20 years. I believe we lost 300,000 people last year,” Trump said earlier this month. 

Regardless of where the “300 million” statistic came from, it’s troubling that Trump said it at all, and that there was little correction from the media. There also doesn’t seem to have been any correction from the White House, as far as I can tell.

Slips like this aren’t just annoying, they have very real implications – especially for pain patients – who already know what happens when prescription opioid deaths are exaggerated. The supply of opioid pain medication gets cut.

When people hear it from the president or White House, it carries weight. 

The Trump administration is not alone in this. In 2016, during the Obama administration, the CDC and the White House Office of National Drug Control Policy released three different estimates in one week on the number of Americans that died from prescription opioids. The numbers ranged from a low of 12,700 to a high of 17,536 deaths in 2015.

Aside from the fact that it literally impacts government policies, the wildly inflated numbers also affect how people respond to them in their day-to-day lives..

While medical professionals and policy makers might recognize that “300 million” or “300 thousand” deaths is an exaggeration, they also may assume that it can’t be that too far off if the president is saying it. 

Such a toll would be catastrophic and signal that the U.S. overdose crisis is getting worse, when the actual number of drug deaths is declining.

This false information perpetuates the idea that all opioids, both legal and illegal, are an extremely deadly problem and need to be restricted.  

Then, when a doctor who saw the clip of Trump on the news goes to treat a patient, he may think twice before writing a hydrocodone prescription because he vaguely remembers something about millions of people overdosing.

Loved ones of patients in pain can also be negatively swayed by such fake statistics. For example, say a mother is prescribed 5 mg doses of Norco for cancer pain. Their adult child may assume that even such a low dose has the potential to be deadly, because of what the president said, and they may discourage their mom from taking it.

Ideally, the White House Communications Office would issue some sort of correction of Trump’s statement. But seeing how this happened a few days ago, and they have yet to address it, I assume such a correction is unlikely to ever happen. And they’re hoping we’ll all forget about it.

Any single drug-related death is too many, and we absolutely should be looking into policies that address overdoses in ways that are proven to help. But when advocates have to instead spend time combating misinformation, it just takes time and resources away from the real problem.

Opioids do cause deaths, but they also give millions of people their lives back by alleviating their pain and allowing them to actually function. 

When we only focus on one side of the equation — especially when that focus is marred by widely inaccurate information — the result is just more pain and suffering.

Medicare Pilot Program Will Use AI To Decide If Pain Treatments Are Worth the Cost    

By Pat Anson

Medicare patients in six states who need epidural steroid injections, cervical fusions, spinal cord stimulators, arthroscopic knee surgery and other treatments for chronic pain will soon have their prior authorization requests reviewed by artificial intelligence (AI) to decide whether the treatments are worth the cost.

The Centers for Medicare & Medicaid Services (CMS) is launching a 6-year pilot program on January 1, 2026 called the Wasteful and Inappropriate Service Reduction Model --- known as “WISeR” for short.

WISeR will cover Original Medicare patients in New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington who seek treatment for chronic pain, impotence, incontinence, and burns or wounds needing skin and tissue substitutes.

WISeR will review over a dozen treatments that CMS considers low-value, potentially unsafe, or suspicious because of prior reports of fraud and wasteful spending. The low-value treatments alone cost Medicare nearly $6 billion in 2022.

“CMS is committed to crushing fraud, waste, and abuse, and the WISeR Model will help root out waste in Original Medicare,” CMS Administrator Dr. Mehmet Oz said in a press release. “Combining the speed of technology and the experienced clinicians, this new model helps bring Medicare into the 21st century by testing a streamlined prior authorization process, while protecting Medicare beneficiaries from being given unnecessary and often costly procedures.”

Under traditional or Original Medicare, most covered services do not require prior authorization, but Medicare Advantage (MA) plans often do. For that reason, CMS is partnering with private MA plans that have more experience using AI and other advanced technologies to process prior authorization requests. If a request is denied by WISeR, the agency says it will then be reviewed before a final decision “by licensed clinicians, not machines.”

CMS claims that WISeR will “expedite decision making” and not change coverage for traditional Medicare beneficiaries, who “retain the freedom to seek care from their provider or supplier of choice.”

Those providers, however, will be incentivized with higher Medicare payments if they participate in WISeR and show they can reduce the use of low value treatments and help lower Medicare spending.  

Pain treatments that will be reviewed under the WISeR Model include these procedures:

  • Electrical Nerve Stimulation  

  • Deep Brain Stimulation for Essential Tremor and Parkinson's Disease

  • Vagus Nerve Stimulation

  • Surgical Removal or Ablation of Nerves

  • Epidural Steroid Injections (excluding facet joint injections)

  • Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fractures

  • Cervical Fusions  

  • Arthroscopic Surgery for Knee Osteoarthritis

  • Percutaneous Image-Guided Lumbar Decompression for Spinal Stenosis

Many of these treatments have already drawn scrutiny for being ineffective or costly. Studies have found that spinal cord stimulation, for example, has no benefit for back pain; while epidural steroid injections, nerve blocks and nerve ablation have been found to have little or no benefit.

‘Perverse Incentives’

Not surprisingly, the WISeR Model has drawn criticism from physicians who perform the procedures, who decry the use of AI and algorithms to make healthcare decisions.

“We firmly believe that (WISeR) will jeopardize patient access to care, create more administrative burdens for physicians, offer perverse payment incentives for third-party vendors, and represent a substantial reversal of progress toward this Administration’s goal of prioritizing patients over paperwork,” a coalition of 23 neurosurgeon organizations wrote in a letter to Dr. Oz.

“Decision criteria to be used by participating vendors — including algorithms, scoring models, and evidence-based guidelines — remain a “black box,” leaving stakeholders with little to no insight into how prior authorization determinations will be made.”

Patient rights groups and some politicians say WISeR will create new roadblocks for Medicare patients needing treatment.

“While prior authorization is often described as a cost-containment strategy, in practice it increases provider burden, takes time away from patients, limits patients’ access to life-saving care, and creates unnecessary administrative burden,” Rep. Ami Bera (D) and Rep. Suzan DelBene (D) said in a recent letter to Dr. Oz.

“The use of prior authorization in Medicare Advantage shows us that, in practice, WISeR will likely limit beneficiaries’ access to care, increase burden on our already overburdened health care work force, and create perverse incentives to put profit over patients.”

About 12% of prior authorization denials by Medicare Advantage insurers were appealed in 2023, and more than 80% of them were overturned, according to the Center for Medicare Advocacy.

An HHS Inspector General's report in 2018 found “widespread and persistent” problems involving denials of care by Medicare Advantage. Another report in 2022 found 13% of denied requests actually met Medicare’s rules and should have been approved.

“(WISeR) is) a backdoor way of putting everybody in a Medicare Advantage plan,” Carrie Graham, executive director of the Medicare Policy Initiative told Cleveland.com. “It’s a first step to getting rid of, or downgrading, the freedom that traditional Medicare provides.”

It’s Rare for Chronic Pain Patients to Overdose on Opioids

By Neen Monty

The Penington Institute is an Australian non-profit public health and drug policy research organization. Its core mission is to study drug use “in a safe, considerate and practical way. We seek solutions, not scapegoats. We strive for positive outcomes, not negative stereotypes.”

A most worthy cause.

Each year, Penington releases Australia’s Annual Overdose Report, the country’s most comprehensive study of overdose trends and impacts. I am not against the work of the Penington Institute. On the contrary, they serve a very necessary purpose and have a noble goal.

However, for several years running, they have demonized chronic pain patients and twisted the statistics to inflate the harms of prescription opioids. And this is generally what I write about. To correct the record.

Here’s the download page to Penington’s 2025 report. It documents how many overdoses and what substances were involved. The report relates to data from the 2023 calendar year. Paging through it, something jumped out at me immediately.

Naturally, I jumped straight to the ‘Opioids’ section. There is a table, with key facts. One of these key facts is:

“From 2019-2023, there were 163 unintentional drug-induced deaths involving pharmaceutical opioids as the sole drug type.”

That’s an average of nearly 33 people who died accidentally every year when pharmaceutical opioids were the sole drug type. 33 people. In a country with 27.4 million people.

Does that sound like an opioid crisis to you? Does that sound like a reason to deny tens of thousands of patients access to safe and effective pain relief?

Do you know what immediately occurred to me when I realised that less than 50 people per year die from prescription opioid overdose?

I remembered this 2023 report from the Therapeutic Goods Administration (Australia’s version of the U.S. Food and Drug Administration), justifying their changes to paracetamol scheduling. That’s acetaminophen for those of you in the U.S.

Paracetamol pack sizes were reduced to 16 tablets per packet and supermarkets could only sell two packs per person. Larger packs were only available at pharmacies, and some required a pharmacist’s approval.

Do you know why they made paracetamol harder to get?

Because 50 Australians were dying every year from paracetamol overdoses, with rates of intentional overdose highest among adolescents and young adults.

There was an outcry when the changes came into effect. Chronic pain patients were again being harmed by policy because a different patient group was overdosing.

Because 50 people die of paracetamol overdoses per year in Australia.

Do you get what I am saying?

Paracetamol is still available over-the-counter in Australia, albeit in smaller pack sizes. And yet opioids are almost impossible to access.

Fewer Australians die from prescription opioid overdoses than from paracetamol overdoses. This was true long before any changes were made in opioid scheduling in 2020, making opioids much harder to get.

Opioid prescribing was already declining in 2020, so there was no need to change opioid prescribing practices. Certainly no medical need. In fact, this policy change caused a great deal of harm to those who live with constant, severe pain, and has had no benefits. For anyone.

Please think about it. Reflect upon it. Make it make sense. How is this anything other than a witch hunt?

Paracetamol kills more people than prescription opioids, yet it’s still available over the counter. And doctors are torturing people who live with painful, progressive and incurable diseases, by denying us access to safe and effective pain relief.

Because 33 people die of prescription opioid overdoses every year. While 50 people die of paracetamol overdoses.

Does Australia have an opioid crisis? No.

Does Australia have a prescription opioid crisis? Also no!

We never had a prescription opioid crisis. And we were never heading for one. Prescription opioid overdoes have been falling in Australia since 2018. Check the statistics.

Unlearn what you have been told and learn the true statistics.

There was no need to make changes in 2020. Yet those changes caused interminable suffering to people who live with constant, severe pain from illness or injury.

Most chronic pain patients are still suffering. Many have died.

Does this seem fair to you? Does this seem right? Does it seem reasonable?

Does any of this seem like good policy?

To be clear, I am not saying that opioids should be available over-the-counter. Please do not twist my words to imply that.

Opioids for severe, daily pain should be managed as they were before 2020. By general practitioners who know their patients well.

There should be no dose ceilings because there is no evidence that dose ceilings reduce overdoses and death. GPs are more than capable of prescribing an appropriate dose and duration to manage severe chronic pain.

Instead, chronic pain patients in Australia are forced to go to a pain management specialist, who barely knows them and rarely understands their pain.

People who live with severe, daily pain from disease and injury have a right to pain relief. We need help.

And this year’s Penington report shows that we are not the ones who are overdosing.

It is time to restore access to safe and effective pain relief for those who desperately need it. Chronic pain kills far more often than the opioids prescribed for chronic pain do. Patients die from heart attacks, strokes, hypertension, and other stress-induced conditions when their pain is not treated.  

The true cause of most overdose deaths is polypharmacy: multiple drugs, both legal and illegal, that are often mixed with alcohol.

Targeting people who live with painful, progressive and incurable diseases and injuries, denying us access to pain medication, is never going to reduce overdoses by illicit drug users. They are two different patient populations.

It is not chronic pain patients who are overdosing.

Neen Monty is a patient advocate in Australia who lives with rheumatoid arthritis and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a progressive neurological disease that attacks the nerves.

Neen is dedicated to challenging misinformation and promoting access to safe, effective pain relief. She has created a website for Pain Patient Advocacy Australia to show that prescription opioids can be safe and effective, even when taken long term. You can subscribe to Neen’s newsletter on Substack, “Arthritic Chick on Chronic Pain.”

Experimental Implant Could Dispense Drugs Inside Joints During Arthritis Flares

By Crystal Lindell

Researchers in the UK are developing an artificial cartilage that could dispense anti-inflammatory and pain relieving medications from within joints during an arthritis flare-up.

The gel-like material, developed by a team at the University of Cambridge, has been designed to respond to changes in pH, a measure of acidity. During flare-ups, arthritic joints become inflamed and slightly more acidic than the surrounding tissue.

As acidity increases, the polymer implant becomes softer and more jelly-like, triggering the release of drug molecules within the joint. In theory, researchers say the drugs would be released precisely where and when they are needed, providing more effective and continuous relief.

“These materials can ‘sense’ when something is wrong in the body and respond by delivering treatment right where it’s needed,” said Stephen O’Neill, PhD, a postdoctoral researcher at Cambridge. “This could reduce the need for repeated doses of drugs, while improving patient quality of life.”

The research was reported in the Journal of the American Chemical Society

The polymer material was developed by a research group in the Department of Chemistry at Cambridge that specializes in designing and building unique materials for a range of potential applications.

“For a while now, we’ve been interested in using these materials in joints, since their properties can mimic those of cartilage,” said lead author Oren Scherman, PhD, Director of the Melville Laboratory for Polymer Synthesis. “But to combine that with highly targeted drug delivery is a really exciting prospect.”

Clinical trials are needed before the material can be used in patients. Researchers say their next steps will be to test the materials in living organisms to evaluate their performance and safety. 

If successful, that could lead to a new generation of responsive biomaterials capable of treating a variety of chronic diseases. The gel could be adapted for placement in different parts of the body.

“It’s a highly flexible approach, so we could in theory incorporate both fast-acting and slow-acting drugs, and have a single treatment that lasts for days, weeks or even months,” said O’Neill.

While it is incredible to see these new advances in pain treatment, it’s also imperative that researchers make sure that they are actually better than the current treatments available. They also need to make sure that the implants are relatively easy to remove in the case of complications.

In the research paper, the authors suggest the implants could be used for rheumatoid and osteoarthritis pain. However, both of those diseases can cause widespread joint pain, so it remains unclear if material needs to be implanted in multiple joints to be effective.

And if the implants can be effective “for days, weeks or even months,” how would they be re-loaded with medication or even fully replaced? Such a process could be very taxing for patients, especially if it requires a trip to the hospital or a doctor’s office each time.

In the original Jurassic Park movie, the character Dr. Ian Malcolm says, “Your scientists were so preoccupied with whether they could, they didn't stop to think if they should.”

I hope these researchers heed that advice. 

Balancing the Risks and Benefits of Kratom

By David Kroll

David Bregger had never heard of kratom before his son, Daniel, 33, died in Denver in 2021 from using what he thought was a natural and safe remedy for anxiety.

By his father’s account, Daniel didn’t know that the herbal product could kill him. The product listed no ingredients or safe-dosing information on the label. And it had no warning that it should not be combined with other sedating drugs, such as the over-the-counter antihistamine diphenhydramine, which is the active ingredient in Benadryl and other sleep aids.

As the fourth anniversary of Daniel’s death approaches, a recently enacted Colorado law aims to prevent other families from experiencing the heartbreak shared by the Bregger family. Colorado Senate Bill 25-072, known as the Daniel Bregger Act, addresses what the state legislature calls the deceptive trade practices around the sale of concentrated kratom products artificially enriched with a chemical called 7-OH.

7-OH, known as 7-hydroxymitragynine, has also garnered national attention. On July 29, 2025, the U.S. Food and Drug Administration issued a warning that products containing 7-OH are potent opioids that can pose significant health risks and even death.

As kratom and its constituents are studied in greater detail, the Centers for Disease Control and Prevention and university researchers have documented hundreds of deaths where kratom-derived chemicals were present in postmortem blood tests. But rarely is kratom deadly by itself. In a study of 551 kratom-related deaths in Florida, 93.5% involved other substances such as opioids like fentanyl.

I study pharmaceutical sciences, have taught for over 30 years about herbal supplements like kratom, and I’ve written about kratom’s effects and controversy.

One Name, Many Products

Kratom is a broad term used to describe products made from the leaves of a Southeast Asian tree known scientifically as Mitragyna speciosa. The Latin name derives from the shape of its leaves, which resemble a bishop’s miter, the ceremonial, pointed headdress worn by bishops and other church leaders.

Kratom is made from dried and powdered leaves that can be chewed or made into a tea. Used by rice field workers and farmers in Thailand to increase stamina and productivity, kratom initially alleviates fatigue with an effect like that of caffeine. In larger amounts, it imparts a sense of well-being similar to opioids.

In fact, mitragynine, which is found in small amounts in kratom, partially stimulates opioid receptors in the central nervous system. These are the same type of opioid receptors that trigger the effects of drugs such as morphine and oxycodone. They are also the same receptors that can slow or stop breathing when overstimulated.

In the body, the small amount of mitragynine in kratom powder is converted to 7-OH by liver enzymes, hence the opioid-like effects in the body. 7-OH can also be made in a lab and is used to increase the potency of certain kratom products, including the ones found in gas stations or liquor stores.

And therein lies the controversy over the risks and benefits of kratom.

‘No Currently Accepted Medical Use’

Because kratom is a plant-derived product, it has fallen into a murky enforcement area. It is sold as an herbal supplement, normally by the kilogram from online retailers overseas.

In 2016, I wrote a series of articles for Forbes as the Drug Enforcement Administration proposed to list kratom constituents on the most restrictive Schedule 1 of the Controlled Substances Act. This classification is reserved for drugs the DEA determines to possess “no currently accepted medical use and a high potential for abuse,” such as heroin and LSD.

But readers countered the DEA’s stance and sent me more than 200 messages that primarily documented their use of kratom as an alternative to opioids for pain.

Others described how kratom assisted them in recovery from addiction to alcohol or opioids themselves. Similar stories also flooded the official comments requested by the DEA, and the public pressure presumably led the agency to drop its plan to regulate kratom as a controlled substance.

But not all of the stories pointed to kratom’s benefits. Instead, some people pointed out a major risk: becoming addicted to kratom itself. I learned it is a double-edged sword – remedy to some, recreational risk to others. A national survey of kratom users was consistent with my nonscientific sampling, showing more than half were using the supplement to relieve pain, stress, anxiety or a combination of these.

Natural Leaf Powder vs Concentrated Extracts

After the DEA dropped its 2016 plan to ban the leaf powder, marketers in the U.S. began isolating mitragynine and concentrating it into small bottles that could be taken like those energy shots of caffeine often sold in gas stations and convenience stores.

This formula made it easier to ingest more kratom. Slowly, sellers learned they could make the more potent 7-OH from mitragynine and give their products an extra punch. And an extra dose of risk.

People who use kratom in the powder form describe taking 3 to 5 grams, the size of a generous tablespoon. They put the powder in capsules or made it into a tea several times a day to ward off pain, the craving for alcohol or the withdrawal symptoms from long-term prescription opioid use.

Since this form of kratom does not contain very much mitragynine – it is only about 1% of the powdered leaf – overdosing on the powder alone does not typically happen.

That, along with pushback from consumers, is why the Food and Drug Administration is proposing to restrict only the availability of 7-OH and not mitragynine or kratom powder. The new Colorado law limits the concentration of kratom ingredients in products and restricts their sales and marketing to consumers over 21.

Even David Bregger supports this distinction. “I’m not anti-kratom, I’m pro-regulation. What I’m after is getting nothing but leaf product,” he told WPRI in Rhode Island last year while demonstrating at a conference of the education and advocacy trade group the American Kratom Association.

Such lobbying with the trade group last year led the American Kratom Association to concur that 7-OH should be regulated as a Schedule 1 controlled substance. The association acknowledges that such regulation is reasonable and based in science.

Potential Use as Medicine

Despite the local and national debate over 7-OH, scientists are continuing to explore kratom compounds for their legitimate medical use.

A $3.5 million NIH grant is one of several that is increasing understanding of kratom as a source for new drugs.

Researchers have identified numerous other chemicals called alkaloids from kratom leaf specimens and commercial products. These researchers show that some types of kratom trees make unique chemicals, possibly opening the door to other painkillers.

Researchers have also found that compounds from kratom, such as 7-OH, bind to opioid receptors in unique ways. The compounds seem to have an effect more toward pain management and away from potentially deadly suppression of breathing. Of course, this is when the compounds are used alone and not together with other sedating drugs.

Rather than contributing to the opioid crisis, researchers suspect that isolated and safely purified drugs made from kratom could be potential treatments for opioid addiction. In fact, some kratom chemicals such as mitragynine have multiple actions and could potentially replace both medication-assisted therapy, like buprenorphine, in treating opioid addiction and drugs like clonidine for opioid withdrawal symptoms.

Rigorous scientific study has led to this more reasonable juncture in the understanding of kratom and its sensible regulation. Sadly, we cannot bring back Daniel Bregger. But researchers can advance the potential for new and beneficial drugs while legislators help prevent such tragedies from befalling other families.

David Kroll, PhD, is a Professor of Natural Products Pharmacology & Toxicology in the Department of Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus.

This article originally appeared in The Conversation and is republished with permission.

5 Myths About Opioids That I Believed, Until I Needed Them

By Crystal Lindell

I had been enduring debilitating pain for months by the time I was given my first hydrocodone prescription for chronic pain in 2013.

At the time, I didn’t even know that hydrocodone was an opioid.

I had only heard of Vicodin being an opioid, and that was only because I lived near the Wisconsin border, where there are lots of Packer fans. The news that former Green Bay quarterback Brett Favre had to go to rehab for his Vicodin use was part of the local conversation.

But I had no idea that hydrocodone was the active ingredient in Vicodin.

It’s been over a decade now, and I have come to rely on opioids to manage the chronic pain I have in my right ribs, which is technically called “intercostal neuralgia.”

Before I needed opioids for pain relief, I used to buy into a lot of common cultural myths about them. Below is a look at what I used to believe, and how my views eventually shifted.

Myth #1: Only People Who ‘Misuse’ Opioids Have Physical Withdrawal

When I got my first hydrocodone prescription, I didn’t know it was a controlled substance with strict limits on how often you can get refills. And I definitely didn’t know that I would go through withdrawal if I stopped taking them abruptly.

My doctor prescribed 10mg pills and the label said: “Take 1-2 every 4-6 hours.”

So, that’s exactly what I did: Two pills every four to six hours.

My pain was (and still is) intense, but at the time I was still trying to keep pace with my pre-chronic pain lifestyle, which meant doing everything possible to push the pain away so that I could work and have a somewhat normal life.

But that meant that I ran out of my prescription early – something I was not aware was even a problem. When the doctor’s office said I would need to wait a couple days for a refill, I didn’t think it would be a big deal. Surely, I could easily ride out a couple of days without hydrocodone, no problem. After all, I had been taking them as prescribed.

Yeah. That’s not what happened. Turns out you actually cannot go from 40 to 80 mg of hydrocodone a day to zero.

I naively went to work that day, and still remember the trauma of spending the entire shift in the bathroom with diarrhea, nausea, horrible flu-like aches, and an odd feeling of anxiety.

Turns out, anyone can go through withdrawal from opioids. There is no magic spell that doctors can cast to give you immunity from it, just because you’re taking opioids exactly as prescribed. Your body doesn’t know the difference.

And that physical withdrawal is also not indicative that you have “a problem.”

In fact, it’s one of the reasons I think the entire conversation around addiction is often more nuanced than people want to admit. Taking a dose to combat withdrawal is often labeled as “misuse” – even though anyone can have withdrawal. 

And anyone who’s been through it knows that you’ll do almost anything to make it stop.

Myth #2: The Best Way to Stop Using Opioids Is Quitting Cold Turkey

There’s a common myth that the best way to stop using an addictive substance is to go cold turkey. That’s usually not true for things like nicotine and alcohol, and it’s also not true for opioids.

I used to believe in the common framing for this. That if you stopped using opioids cold turkey, made it through 72 hours of withdrawal, and then took just one dose, it would reset the whole process. You’d have to go through withdrawal all over again.

That’s not true. In fact, taking a dose after going longer than usual without one is often part of the tapering process that works best for getting off opioids. 

Ideally, you taper off slowly by lowering the amount you’re taking each day. So, if you’re on 40mg of hydrocodone a day, the best way to stop using it is to take 35mg daily for a week or so, then 30 mg, and so on until you get down to zero.

That’s the best way to reach success long-term and actually get off the medication, if that is your goal.

If you’re looking for more realistic tips on how to stop taking opioids, see “A Survival Guide for Opioid Withdrawal” that I wrote for PNN with my partner a few years ago. You can trust the advice because we learned it ourselves the hard way.

Myth #3: Opioid Doses Last as Long as Manufacturers Claim

I was eventually prescribed extended-release morphine pills for my chronic pain, and was told that each one should last a full eight hours. I was also told that hydrocodone should last four to six hours.

Unfortunately, neither of those things are true. So-called “extended release” morphine lasts about four hours, while the short-acting hydrocodone can stop working in just two or three hours.

So, it’s not wise to take another dose whenever your pain comes back. If you do that, you’ll end up running out of your prescription early every month.

Instead, you should expect to go through periods throughout the day when your pain starts to come back – and then you have to count down until your next dose.

Myth #4: Even One Dose of an Opioid Creates a High Risk of Addiction

Before I started taking opioids, I honestly believed the myth that just one 10mg dose of Vicodin could result in life-long addiction.

In reality, that’s nearly impossible. In fact, even among patients who take opioids long-term, the rate of addiction is still incredibly low. Estimates vary widely, but according to experts who have studied it, people who take opioids over long periods have addiction rates of 1 to 3 percent.   

Opioids are often framed as being so addictive that anyone can get hooked, so any exposure to them is dangerous and risky. In reality, low-dose opioids are incredibly safe, and most patients taking prescription opioids never develop an addiction to them

Myth #5: If Someone Is ‘Really’ in Pain, Doctors Will Prescribe Opioids

I am a little ashamed to admit this, but I used to think of a Vicodin prescription as an indicator of whether or not someone’s pain was actually severe.

If a doctor prescribed Vicodin to someone, that meant they were in “real” pain.

Boy, was I wrong.

While dealing with pain myself, I quickly learned that doctors will often ignore severe pain in patients because they don’t want to deal with the hassle of prescribing a controlled substance. That reluctance has only gotten worse since 2013. Much worse.

These days, doctors withhold opioid medication from post-op patients, cancer patients, palliative care patients, and even hospice patients. All of them are still in very real pain though.

Whether or not a doctor validates your pain with an opioid prescription has no bearing on how severe your pain actually is.

There’s a lot of misinformation about opioids and these are just some of the common myths perpetuated about them. While it’s understandable to believe them if you’ve actually never needed opioids, I encourage everyone to keep an open mind. After all, if you wait until you or a loved one needs opioids to see the truth, it may be too late.

VA Researchers Say Opioid Guidelines Should Include Cancer Patients

By Pat Anson

Most medical guidelines that limit the use of opioid pain medication are intended only for patients suffering from “non-cancer” pain. The CDC, for example, says that its guideline “does not apply to patients undergoing cancer-related pain treatment,” because the potential for addiction and overdose “might not be relevant” to patients at risk of dying.

That long-held policy is now being questioned. In a study published in CANCER, the medical journal of the American Cancer Society, VA researchers say cancer patients are living longer and may be at risk of “persistent opioid use.”

The study, led by researchers at the VA Medical Center in Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, followed over 9,000 veterans who had surgery for early-stage cancer, mostly prostate, colon, bladder or lung cancers. About a third of those patients also needed chemotherapy, immunotherapy or radiation therapy.  

Thirteen months after surgery, about one in ten patients (10.6%) were still prescribed opioids for pain relief. And about 4% of them were co-prescribed benzodiazepines for anxiety, a combination of medications that some consider risky.

Although none of the veterans overdosed from taking opioids, and less than one percent (0.78%) were diagnosed with opioid use disorder, researchers say stronger measures are needed to limit the use of opioids by cancer patients.

“Minimizing opioid exposure associated with cancer treatment while providing effective pain control will decrease long-term health risks among cancer survivors,” said lead author Marilyn Schapira, MD, Professor of Medicine at the University of Pennsylvania and Co-Director at the Center for Health Equity Research at the VA Medical Center.

“Prescription opioid practices associated with cancer treatment may lead to unsafe and long-term opioid treatment (LTOT) and the related adverse outcomes of opioid use disorder, opioid overdose, and nonoverdose adverse events, including suicide.”

Schapira and her colleagues say medical guidelines that exclude cancer patients from opioid prescribing limits, such as the CDC guideline and the Department of Defense/Veterans Affairs guideline, should be rewritten.

“There may be benefits to extending general guidelines regarding prescription opioids to those facing cancer treatment in consideration of health and well-being during the years of survivorship," researchers concluded. “Efforts should be taken to mitigate long-term opioid use and its potential adverse effects in this population. This is especially true because cancer is increasingly recognized as a chronic condition, and survivors of cancer are living longer.”

Cancer patients with a history of chronic pain, greater comorbidities, lower socioeconomic status, and those who received chemotherapy were said to be at “especially high risk of opioid use in the year after surgery.”

Regardless of what the guidelines say, many U.S. patients being treated for cancer already have trouble getting opioids for pain control. A recent study found a 24% decline in opioid prescribing to cancer patients on Medicare after the CDC’s 2016 guideline. Another study found the number of cancer patients seeking treatment for pain in hospital emergency rooms doubled. About a quarter of the patients had cancer pain so severe they were admitted.  

Other studies have found that cancer patients are getting smaller and fewer doses of opioids, while some can’t get them at all. A recent survey of palliative care doctors in New York City found that nine out of ten (88%) reported frequent obstacles in getting opioids for their patients due to tight supplies at pharmacies. Nearly a third said the shortages resulted in sub-optimal care for their patients.

One of the more egregious examples of a cancer patient being unable to get opioids was the case of April Doyle, a California woman with metastatic breast cancer who couldn’t get her Norco prescription filled at a Rite Aid pharmacy. April recorded a tearful video in the pharmacy parking lot and shared it online, where it went viral. Outrage over the incident led to an apology from Rite Aid and her prescription being filled. April died a year later at the age of 42, leaving behind a 9-year-old son.

How To Get More Pain Relief From Rx Opioids

By Drs. Forest Tennant, Martin Porcelli and Scott Guess

Due to a multitude of legal restrictions and biases, many persons living with pain who take opioid medication can’t get enough relief to function, be comfortable, and have quality of life.

Summarized below are some of the ways we have found to boost or enhance the pain-relieving effect of prescription opioids.

Take a Booster (Potentiator)

Opioids trigger the endorphin receptor to relieve pain. If you simultaneously take a medicine or supplement that triggers a different receptor or suppresses inflammation, pain relief is enhanced. This boosting effect is the reason opioids are combined with acetaminophen or aspirin in pain medications such as Vicodin or Percocet.

Here is a list of potential non-prescription boosters. You may have to experiment to find one or two that boost the potency of your opioid. You can swallow the booster with your oral opioid or take the booster within 15 minutes after taking the opioid.

  • Taurine 1000 mg

  • Glutamine 1000 mg

  • Lion’s Mane mushrooms

  • Quercetin

  • Benadryl

  • St. John’s wort

  • White willow bark

  • Cannabidiol (CBD)

  • Kava

  • Palmitoylethanolamide (PEA) 300 to 600 mg

Under the Tongue vs Swallowing

A medication dissolved under the tongue (sublingually) is always more potent than if you swallow it whole. That’s because digestion in the stomach and intestines may wipe out as much as 50% of an oral opioid’s pain relief capability.

Try dissolving an opioid tablet under your tongue. You may find it much more effective, as it will enter the bloodstream faster. We recommend starting with half your usual dose and increase it as needed, being careful not to exceed your usual dose. Discuss this practice with your medical practitioner.

Don’t Forget Aspirin

Aspirin has been disparaged to the point that people are afraid to take it. It is still one of the very best opioid boosters. Dissolve it under your tongue to avoid stomach upset or bleeding.

Receptor Health

The central nervous system has many receptors (“action points”) that relieve pain. They need to stay healthy and active to provide maximal pain relief. A good nutrition program that consists of daily protein, vitamin D, and magnesium helps keep nerve receptors healthy and maximizes opioid pain relief.

Bedtime Preparation

Some medicinals taken at bedtime have the effect of making the next day’s opioids more effective. Here are some suggestions:

  • Metformin 500 mg + L-Theanine 200 mg

  • Tryptophan 500 to 1000 mg

  • Amitriptyline

  • Pentoxifylline

Cannabis

Some persons find that cannabis provides significant pain relief, while others experience little or no relief.

Do not take cannabis products within four hours before or after an opioid dosage to avoid over-sedation, loss of coordination, and mental deficiency.

Kratom

Kratom is the only non-prescription herbal supplement that has opioid-like effects. It comes in a variety of forms, usually natural leaf powder that is sold in capsules, edibles or drinks.

Kratom can be simultaneously taken with opioids, but be wary of synthetic or concentrated kratom as its potency may be unknown or too high.

All persons who take opioids for pain relief should find a kratom form and dosage that relieves pain. Given today’s adverse attitudes and restrictions on opioids, a person relying on prescription opioids alone must face the fact that their medical practitioners may end or reduce their opioid therapy at any time. When this happens, you may have to rely on kratom.

Prescription Boosters

Many physicians prescribe non-opioid medications for pain relief, such as gabapentin (Neurontin), clonidine, tizanidine, baclofen, and pregabalin (Lyrica). These can also be used to boost the potency of opioids. Take these medications within four hours before or after your opioid dose.

Forest Tennant, MD, DrPH, is retired from clinical practice but continues his research on the treatment of intractable pain and arachnoiditis. Readers interested in learning more about his research should visit the Tennant Foundation’s website, Arachnoiditis Hope. You can subscribe to its research bulletins here.

Martin J. Porcelli, DO, is a family medicine doctor in Pomona, CA and is affiliated with Casa Colina Hospital.

Scott Guess, PharmD, operates an independent pharmacy and clinic in Atascadero, CA that specializes in pain management and arachnoiditis.

The Tennant Foundation gives financial support to Pain News Network and sponsors PNN’s Patient Resources section. 

7 Tips to Help Fight a Health Insurance Denial

By Lauren Sausser, KFF Health News

When Sally Nix found out that her health insurance company wouldn’t pay for an expensive, doctor-recommended treatment to ease her neurological pain, she prepared for battle.

It took years, a chain of conflicting decisions, and a health insurer switch before she finally won approval. She started treatment in January and now channels time and energy into helping other patients fight denials.

“One of the things I tell people when they come to me is: ‘Don’t panic. This isn’t a final no,’” said Nix, 55, of Statesville, North Carolina.

To control costs, nearly all health insurers use a system called prior authorization, which requires patients or their providers to seek approval before they can get certain procedures, tests, and prescriptions.

Denials can be appealed, but nearly half of insured adults who received a prior authorization denial in the past two years reported the appeals process was either somewhat or very difficult, according to a July poll published by KFF, a health information nonprofit that includes KFF Health News.

“It’s overwhelming by design,” because insurers know confusion and fatigue cause people to give up, Nix said. “That’s exactly what they want you to do.”

The good news is you don’t have to be an insurance expert to get results, she said. “You just need to know how to push back.”

Here are tips to consider when faced with a prior authorization denial:

1. Know your insurance plan

Do you have insurance through your job? A plan purchased through healthcare.gov? Medicare? Medicare Advantage? Medicaid?

These distinctions can be confusing, but they matter a great deal. Different categories of health insurance are governed by different agencies and are therefore subject to different prior authorization rules.

For example, federal marketplace plans, as well as Medicare and Medicare Advantage plans, are regulated by the U.S. Department of Health and Human Services. Employer-sponsored plans are regulated by the Department of Labor. Medicaid plans, administered by state agencies, are subject to both state and federal rules.

Learn the language specific to your policy. Health insurance companies do not apply prior authorization requirements uniformly across all plans. Read your policy closely to make sure your insurer is following its own rules, as well as regulations set by the state and federal government.

2. Work with your provider to appeal

Kathleen Lavanchy, who retired in 2024 from a job at an inpatient rehabilitation hospital in the Philadelphia area, spent much of her career communicating with health insurance companies on behalf of patients.

Before you contact your health insurer, call your provider, Lavanchy said, and ask to speak to a medical care manager or someone in the office who handles prior authorization appeals.

The good news is that your doctor’s office may already be working on an appeal.

Medical staffers can act as “your voice,” Nix said. “They know all the language.”

You or your provider can request a “peer-to-peer” review during the appeals process, which allows your doctor to discuss your case over the phone with a medical professional who works for the insurance company.

3. Be organized

Many hospitals and doctors use a system called MyChart to organize medical records, test results, and communications so that they are easily accessible. Similarly, patients should keep track of all materials related to an insurance appeal — records of phone calls, emails, snail mail, and in-app messages.

Everything should be organized, either digitally or on paper, so that it can be easily referenced, Nix said. At one point, she said, her own records proved that her insurance company had given conflicting information. The records were “the thing that saved me,” she said.

“Keep an amazing paper trail,” she said. “Every call, every letter, every name.”

Linda Jorgensen, executive director of the Special Needs Resource Project, a nonprofit offering online resources for patients with disabilities and their families, has advised patients who are fighting a denial to specifically keep paper copies of everything.

“If it isn’t on paper, it didn’t happen,” she said.

Jorgensen, who serves as a caregiver to an adult daughter with special needs, created a free form you can print to help guide you when taking notes during phone calls with your insurance company. She advised asking the insurance representative for a “ticket number” and their name before proceeding with the conversation.

4. Appeal as soon as possible

The silver lining is that most denials, if appealed, are overturned.

Medicare Advantage data published by KFF in January found that nearly 82% of prior authorization denials from 2019 through 2023 were partially or fully overturned upon appeal.

But the clock is ticking. Most health plans give you only six months to appeal the decision, according to rules laid out in the Affordable Care Act.

“Don’t dillydally,” Jorgensen advised, especially if you’re sending a paper appeal, or any supporting documents, through the U.S. Postal Service. She recommends filing quickly, and at least four weeks before the deadline.

For the sake of speed, some people are turning to artificial intelligence for help crafting customizable appeal letters.

5. Ask your HR department for help

If you get your health insurance through an employer, there’s a good chance your health plan is “self-funded” or “self-insured.” That means your employer contracts with a health insurance company to administer benefits, but your employer shoulders the cost of your care.

Why does that matter? Under self-funded plans, decisions about what is or isn’t covered ultimately rest with your employer.

Let’s say, for example, your doctor has recommended that you undergo surgery, and your insurer has denied prior authorization for it, deeming the procedure “not medically necessary,” a phrase commonly used. If your plan is self-funded, you can appeal to the human resources department at your job, because your employer is on the hook for your health care costs — not the insurer.

Of course, there’s no guarantee your employer will agree to pay. But, at the very least, it’s worth reaching out for help.

6. Find an advocate

Many states operate free consumer assistance programs, available by phone or email, which can help you file an appeal. They can explain your benefits and may intervene if your insurance company isn’t complying with requirements.

Beyond that, some nonprofit advocacy groups, such as the Patient Advocate Foundation, might help. On the foundation’s website is guidance about what to include in an appeal letter. For those battling severe disease, foundation staffers can work with you one-on-one to fight a denial.

7. Make noise

We’ve written about this before. Sometimes, when patients and doctors shame insurers online, denials get overturned.

The same holds when patients contact lawmakers. State laws regulate some categories of health insurance, and when it comes to setting policy, state lawmakers have the power to hold insurance companies accountable.

Reaching out to your legislator isn’t guaranteed to work, but it might be worth a shot.

Finally, if you’re interested in sharing your experiences with a journalist, fill out this form. We’d like to hear from you.

KFF Health News is a national newsroom that produces in-depth journalism about health issues.